BioLife Solutions Inc (NASDAQ:BLFS) VP Todd Berard sold 3,000 shares of BioLife Solutions stock in a transaction on Friday, September 21st. The stock was sold at an average price of $17.23, for a total value of $51,690.00. Following the completion of the sale, the vice president now directly owns 37,583 shares of the company’s stock, valued at approximately $647,555.09. The transaction was disclosed in a document filed with the SEC, which is available at this link.

BioLife Solutions stock opened at $17.53 on Wednesday. BioLife Solutions Inc has a 12 month low of $4.63 and a 12 month high of $26.35.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, August 9th. The medical equipment provider reported $0.05 EPS for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.01. The business had revenue of $5.18 million during the quarter, compared to analyst estimates of $5.20 million. BioLife Solutions had a return on equity of 2.24% and a net margin of 1.76%. analysts predict that BioLife Solutions Inc will post 0.15 EPS for the current fiscal year.

BLFS has been the subject of a number of research analyst reports. B. Riley initiated coverage on BioLife Solutions in a report on Thursday, June 7th. They issued a “buy” rating and a $14.00 target price for the company. Northland Securities reissued a “buy” rating and issued a $18.00 target price on shares of BioLife Solutions in a report on Friday, August 10th. Maxim Group reissued a “buy” rating and issued a $26.00 target price on shares of BioLife Solutions in a report on Wednesday, September 5th. BidaskClub lowered BioLife Solutions from a “strong-buy” rating to a “buy” rating in a report on Friday, September 7th. Finally, TheStreet raised BioLife Solutions from a “d” rating to a “c-” rating in a report on Tuesday, September 11th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $22.33.

Several hedge funds have recently added to or reduced their stakes in BLFS. Casdin Capital LLC purchased a new position in shares of BioLife Solutions in the 2nd quarter worth $11,410,000. Renaissance Technologies LLC boosted its stake in shares of BioLife Solutions by 644.2% in the 2nd quarter. Renaissance Technologies LLC now owns 206,900 shares of the medical equipment provider’s stock worth $2,361,000 after buying an additional 179,100 shares during the last quarter. Sandler Capital Management purchased a new position in shares of BioLife Solutions in the 2nd quarter worth $1,723,000. Perkins Capital Management Inc. boosted its stake in shares of BioLife Solutions by 473.8% in the 2nd quarter. Perkins Capital Management Inc. now owns 157,800 shares of the medical equipment provider’s stock worth $1,800,000 after buying an additional 130,300 shares during the last quarter. Finally, Granahan Investment Management Inc. MA purchased a new position in shares of BioLife Solutions in the 2nd quarter worth $1,361,000. Hedge funds and other institutional investors own 27.77% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Further Reading: Hedge Funds Explained

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.